The NAP test will be performed using a nitrosating agent such as Na15NO2, and the products will be identified and quantified using 15N-NMR. It’s interesting!
On Tuesday, May 27th, Anna Simonetto, R&D Researcher, presented the case study: “The Hunt for NDSRIs: Unveiling Hidden Threats with the Novel ¹⁵N-Enriched NAP Test”.
In her talk, Anna delved into the complexity of nitrosamine impurities, presenting Dipharma’s risk assessment protocol and showcasing several innovative investigative advancements developed by our team, including the groundbreaking application of ¹⁵N-NMR methodology.
Her presentation provided practical insights into how science and technology converge to tackle one of the most pressing challenges in pharmaceutical development today. It was well received by the audience, and several questions were raised at the end, demonstrating the strong interest in the innovative approach developed by Anna.